May 11, 2016
Takeda Pharmaceutical has called off the development of TAK-648, which was in PI for the treatment of diabetic nephropathy, according to its pipeline update unveiled on May 10. In a document released upon the company’s FY2015 earnings announcement, Takeda revealed...read more